US · LNTH · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Lantheus Holdings, Inc. (LNTH) intrinsic value and stock valuation
$102.10as of 2026-11-21 · Mkt cap 6.61B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Lantheus Holdings, Inc. DCF and intrinsic value
InvestorsCraft values LNTH with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from LNTH’s statements →
Lantheus Holdings, Inc. Graham Number
Graham Number: $35.46d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Praxis Precision Medicines, Inc. (PRAX) $300.43
- Crinetics Pharmaceuticals, Inc. (CRNX) $84.95
- Hinge Health, Inc. (HNGE) $105.78
- Amneal Pharmaceuticals, Inc. (AMRX) $21.12
- ACADIA Pharmaceuticals Inc. (ACAD) $17.11
- Indivior Pharmaceuticals Inc (INDV) $36.28
- Supernus Pharmaceuticals, Inc. (SUPN) $28.61
- Bausch Health Companies Inc. (BHC) $8.22
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.3B | $935.1M | $425.2M |
| Operating income | $310.8M | $457M | $364.6M | $36.2M | -$-60.83M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$-71.28M |
| EPSd | $3.41M | $4.36M | $4.65M | $397.2K | -$-1.06M |
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M |
| Capital expenditure | -$-36.09M | -$-51.62M | -$-46.55M | -$-18.35M | -$-12.14M |
| Free cash flow | $354.1M | $493.1M | $258.7M | $263.4M | $41.8M |
| Total assets | $2.23B | $1.98B | $1.65B | $1.32B | $863.8M |
| Total debt | $619.4M | $619.4M | $617M | $583.5M | $191.3M |
| Net debt | $260.3M | -$-293.38M | -$-96.71M | $167.9M | $92.8M |
| Total equity | $1.09B | $1.09B | $815.9M | $447.2M | $464.4M |
| Cash and short-term investments | $359.1M | $912.8M | $713.7M | $415.7M | $98.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.3B | $935.1M | $425.2M |
| Cost of revenue | $599.7M | $545.6M | $586.9M | $353.4M | $237.5M |
| Gross profit | $942M | $988.3M | $709.5M | $581.7M | $187.7M |
| Research and development expenses | $177.3M | $168.1M | $77.7M | $311.7M | $45M |
| Selling, general and administrative expenses | $453.8M | $371.6M | $267.2M | $233.8M | $218.8M |
| Other expenses | $0.00 | -$-8.41M | $0.00 | $0.00 | -$-15.26M |
| Operating expenses | $631.1M | $531.3M | $344.9M | $545.5M | $248.5M |
| Cost and expenses | $1.23B | $1.08B | $931.8M | $898.9M | $486M |
| Interest income | $23.4M | $36.8M | $19.6M | $2.61M | $40K |
| Interest expense | $19.8M | $19.7M | $20M | $7.18M | $7.75M |
| Depreciation and amortization | $70.1M | $64.6M | $60M | $47.9M | $42.3M |
| Ebitda | $403.6M | $515.3M | $491M | $81.8M | -$-25M |
| Operating income | $310.8M | $457M | $364.6M | $36.2M | -$-60.83M |
| Total other income/expenses, net | $2.96M | -$-26M | $46.3M | -$-9.48M | -$-14.21M |
| Income before tax | $313.8M | $431M | $410.9M | $26.7M | -$-75.04M |
| Income tax expense | $80.2M | $118.5M | $84.3M | -$-1.35M | -$-3.76M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$-71.28M |
| Weighted average shares outstanding | $67.5M | $69.2M | $68.3M | $68.5M | $67.5M |
| Weighted average diluted shares outstanding | $68.4M | $71.7M | $70.2M | $70.7M | $67.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $359.1M | $912.8M | $713.7M | $415.7M | $98.5M |
| Net receivables | $358.6M | $321.3M | $284.3M | $213.4M | $89.3M |
| Inventory | $64.7M | $68M | $64M | $35.5M | $35.1M |
| Total current assets | $900M | $1.33B | $1.09B | $677.6M | $235.8M |
| Property, plant and equipment, net | $163.7M | $212.9M | $192M | $141.2M | $125.6M |
| Goodwill and intangible assets | $962.3M | $223M | $213.2M | $376.5M | $409.7M |
| Long-term investments | $42.2M | $39.5M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.33B | $653.7M | $565.3M | $643.6M | $628M |
| Total assets | $2.23B | $1.98B | $1.65B | $1.32B | $863.8M |
| Accounts payable | $42.9M | $34.6M | $41.2M | $20.6M | $20.8M |
| Short-term debt | $740K | $970K | $820K | $350K | $11.6M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $333.4M | $240.5M | $187.4M | $247.7M | $90.5M |
| Long-term debt | $618.7M | $618.5M | $616.1M | $583.2M | $179.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $804.2M | $651.8M | $647.9M | $626.4M | $308.9M |
| Capital lease obligations | $50M | $53.2M | $54.5M | $25.4M | $16.6M |
| Total liabilities | $1.14B | $892.3M | $835.3M | $874.1M | $399.4M |
| Common stock | $720K | $710K | $700K | $690K | $680K |
| Retained earnings | $679.5M | $445.9M | $133.5M | -$-193.16M | -$-221.22M |
| Accumulated other comprehensive income (loss) | -$-1.31M | -$-1.61M | -$-1.04M | -$-1.26M | -$-480K |
| Total equity | $1.09B | $1.09B | $815.9M | $447.2M | $464.4M |
| Total investments | $42.2M | $39.5M | $0.00 | $0.00 | $0.00 |
| Total debt | $619.4M | $619.4M | $617M | $583.5M | $191.3M |
| Net debt | $260.3M | -$-293.38M | -$-96.71M | $167.9M | $92.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$-71.28M |
| Depreciation and amortization | $70.1M | $64.6M | $60M | $47.9M | $42.3M |
| Stock-based compensation | $0.00 | $76.4M | $50.5M | $29.3M | $15.9M |
| Change in working capital | -$-44.23M | $2.05M | -$-171.2M | -$-75.06M | -$-15.15M |
| Accounts receivable | -$-17.89M | -$-37.69M | -$-68.64M | -$-128.46M | -$-33.1M |
| Inventory | -$-9.37M | -$-2.67M | -$-36.22M | -$-7.51M | -$-3.55M |
| Accounts payable | -$-2.49M | -$-8.8M | $17.2M | $300K | $5.42M |
| Net cash provided by operating activities | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M |
| Investments in property, plant and equipment | -$-41.5M | -$-79.62M | -$-46.55M | -$-18.35M | -$-12.14M |
| Acquisitions, net | -$-575.67M | -$-80.91M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-627.17M | -$-226.01M | $5.94M | -$-276.55M | $3.68M |
| Common stock issued | $10.9M | $3.45M | $1.93M | $1.38M | $770K |
| Common stock repurchased | -$-300.02M | -$-100M | $0.00 | -$-75M | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-316.58M | -$-118.54M | -$-13.06M | $311.7M | -$-39.33M |
| Net change in cash | -$-553.66M | $199.2M | $298M | $316.6M | $18M |
| Cash at end of period | $360.8M | $914.5M | $715.3M | $417.2M | $100.7M |
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M |
| Capital expenditure | -$-36.09M | -$-51.62M | -$-46.55M | -$-18.35M | -$-12.14M |
| Free cash flow | $354.1M | $493.1M | $258.7M | $263.4M | $41.8M |
Line items
Line items
Line items
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
- CEO
- Mary Anne Heino
- Employees
- 1.19K
- Beta
- -0.06
Included in
Explore
Frequently asked questions
What is the intrinsic value of Lantheus Holdings, Inc. (LNTH)?
Lantheus Holdings, Inc. (LNTH) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LNTH undervalued?
LNTH trades at a price of $102.10 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.